Home » Stocks » AXLA

Axcella Health, Inc. (AXLA)

Stock Price: $5.78 USD -0.07 (-1.20%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $5.69 -0.09 (-1.56%) Jan 26, 4:53 PM
Market Cap 216.99M
Revenue (ttm) n/a
Net Income (ttm) -57.05M
Shares Out 36.94M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $5.78
Previous Close $5.85
Change ($) -0.07
Change (%) -1.20%
Day's Open 5.86
Day's Range 5.72 - 5.98
Day's Volume 57,401
52-Week Range 2.25 - 7.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

24/7 Wall Street - 1 month ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CTMX, KLDO, MGTA
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Seeking Alpha - 2 months ago

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Zacks Investment Research - 2 months ago

Axcella (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabo...

Business Wire - 4 months ago

--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex ...

Zacks Investment Research - 5 months ago

Axcella Health (AXLA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for tre...

Zacks Investment Research - 5 months ago

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

24/7 Wall Street - 6 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CTMX, KLDO, MGTA
Zacks Investment Research - 6 months ago

Is (AXLA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 6 months ago

Axcella Health (AXLA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Forbes - 7 months ago

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: AGEN, ATOM, EYPT, MGEN
Zacks Investment Research - 7 months ago

Axcella Health Inc. (AXLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 7 months ago

Is (AXLA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

An alarming rise in the number of coronavirus cases results in volatility in the market and raises the appeal of defensive stocks

Other stocks mentioned: ABBV, AWR, BGS, CLX
Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor of Axcella Health

24/7 Wall Street - 7 months ago

The stock market’s fall from February through March was monumental, bringing on the fastest bear market we have seen in our lives.

Other stocks mentioned: FLY, FMCC, FNMA, GLOG, GPP, PGEN, SNCR, ZYNE
Benzinga - 7 months ago

Axcella Health (NASDAQ: AXLA) shares are trading higher on Thursday, after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $28 per share.

Benzinga - 8 months ago

Axcella Health Inc (NASDAQ: AXLA) shares were soaring Wednesday following a clinical readout from the company.

Zacks Investment Research - 9 months ago

Axcella Health Inc. (AXLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 11 months ago

Axcella Health: Rough Sledding, But Still In The Game

Seeking Alpha - 1 year ago

Liver Therapy Forum weekly digest provides an overview on therapeutics in development for hepatic encephalopathy in 2019. The focus this week is on Axcella Health.

About AXLA

Axcella Health, a clinical-stage biotechnology company, researches and develops endogenous metabolic modulators (EMMs) for the treatment of complex diseases and improving health in the United States. It offers AXA1665 for use in treating overt hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic steatohepatitis; AXA2678 for use in treating muscle atrophy; and AXA4010 to target multiple biological pathways to support normal structures and functions of the blood. The company was formerly known as Newco LS16, Inc. and changed its nam... [Read more...]

Industry
Biotechnology
IPO Date
May 9, 2019
CEO
William R. Hinshaw Jr.
Employees
66
Stock Exchange
NASDAQ
Ticker Symbol
AXLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Axcella Health stock is "Buy." The 12-month stock price forecast is 16.11, which is an increase of 178.72% from the latest price.

Price Target
$16.11
(178.72% upside)
Analyst Consensus: Buy